期刊文献+

VEGFIL-6在宫颈癌中的表达及其二者的相互关系 被引量:2

The Expression of VEGF and IL-6 in Cervical Cancer and the Relationship between the Two
下载PDF
导出
摘要 目的:对不同类型的宫颈癌组织中血管内皮生长因子(vascularendothelialgrownfactor,VEGF)、白细胞介素-6(Interleukin-6,IL-6)的表达进行定量分析,以进一步探讨VEGF、IL-6在宫颈癌发病中的作用。方法:选取宫颈癌石蜡组织标本50例和10例正常宫颈组织作对照,通过流式细胞检测方法测定VEGF、IL-6的相对含量。结果:VEGF在鳞癌、腺癌中的表达明显高于正常宫颈组织﹙P﹤0.01,P﹤0.01),且VEGF在腺癌中的表达明显高于在鳞癌中的表达(P﹤0.05);VEGF在晚期癌中的表达明显高于早期癌中的表达(P﹤0.01)。IL-6在淋巴结转移者的表达明显高于无淋巴结转移者(P﹤0.05),在中低分化组的表达明显高于高分化组的表达(P﹤0.01),﹤40岁者分别与40~59岁者、≥60岁者比较随年龄增加IL-6增高,统计学上有显著意义(P﹤0.01,P﹤0.01)。结论:VEGF、IL-6与宫颈癌的发生有关,并可作为判断宫颈癌恶性程度和评价预后的指标。 To explore the important role of VEGF and/or IL-6 in pathogenesis of the cervical cancer and to analyze the expression of VEGF and IL-6 using the quantitative analysis in variant cervical cancer. Methods: The expression of VEGF and IL-6 was detected by FCM in the tumorous tissues from 50 cervical cancer subjects and 10 normal cervical tissues. Results: The expression of VEGF was significantly higher in squamous cell carcinoma and adenocarcinoma than that in normal cervical tissues (P〈0.01, P〈0.01). Moreover, the expression of VEGF in adenocarcinoma and ≥ stage II was markedly higher than that in squamous cell carcinoma and ≤stage I (P〈0.05, P〈0.01), respectively. However, the expression of IL-6 was markedly increased in lymph node metastasis group and low histological differentiation group, compared to the lymph node non-metastasis group and high histological differentiation group (P〈0.05, P〈0.01), respectively. The expression was higher in the group of patients younger than 40, compared to the patients group with the age of 40 to 59 and over 60 respectively, which was also age-dependent (P〈0.01, P〈0.01). Conclusions: Both VEGF and IL-6 are involved in the pathogenesis of cervical cancer, and measurement of expression of VEGF and IL-6 may be developed as a means to evaluate the malignant degree and prognosis of cervical cancer.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2005年第22期1287-1289,共3页 Chinese Journal of Clinical Oncology
关键词 宫颈癌 血管内皮生长因子 白细胞介素-6 定量分析 Cervical cancer VEGF IL-6 Ouantitative Analysis
  • 相关文献

参考文献10

  • 1Obermair A, Kucera E, Mayerhofer K, et al. Vascular endothelial growth Factor (VEGF) in human breast cancer: Correlation with disease-free survival [J]. IntJ Cancer, 1997, 74(4):455~458.
  • 2Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia [J].J Natl Cancer Inst, 1995, 87(16):1237 ~ 1245.
  • 3KodamaJ, Seki N, Tokumo K, et al. Vascular endothelial growth factor is implicated in early invasion in cervical cancer [J]. Eur J Cancer, 1999, 35(3):485~489.
  • 4Tokumo K, Kodama J, Seki N, et al. Different angiogenic pathways in human cervical cancers [J]. Gynecol Oncol, 1998, 68(1):38 ~44.
  • 5Lin HH, Cheng WF, Chan KW, et al. Risk factors for recurrence inpatients with stage IB, ⅡA, and ⅡB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation [J]. Obstet Gynecol, 1996, 88(2):274~279.
  • 6Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells [J]. Cancer Res, 1997, 57(18) :3924 ~3928.
  • 7Castrilli G, Tatone D, Diodoro MG, et al. Interluekin 1-alpha and Interluekin-6 promote the in vitro growth of both normol and neoplastic human cervical epithelial cells [J]. Br J Cancer,1997, 75(6):855~859.
  • 8Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and interleukin-6 solube receptor regulate proliferation of normal,human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro [J]. AmJ Pathol,1995, 146(4):944~952.
  • 9Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 in Cervical-Cancer: The Relationship with VEGF [J]. Gynecol Oncol, 2001,82 (1) :49~ 56.
  • 10Cohen T, Nahari D, Cerem LW, et al. Interleukin-6 Induces the Expression of Vascular Endothelial Growth Factor [J]. J Biol Chem, 1996, 271(2):736~741.

同被引文献11

  • 1刘丽丽,战雪梅,孙崇伟,孙莉莉.转录信号传导子与激活子3在宫颈癌组织中的表达及临床意义[J].中华肿瘤防治杂志,2007,14(6):447-449. 被引量:6
  • 2Monter-Julian F A. The soluble IL 6 receptors: serum levels and biological function[J]. Cell Mol ( Noisy-le-grand), 2001,47 ( 4 ) 583-597.
  • 3Wei L H,Kuo M L,Chen C A, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway[J]. Oncogene, 2003, 22(10):1517-1527.
  • 4Niu G, Wright K L, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis[J] . On cogene,2002, 21(13): 2000-2008.
  • 5Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis [J]. Oncogene, 2000, 19(21): 2474- 2488.
  • 6Page C, Huang M,Jin X, et al. Elevated phosphorylation of AKT and Star3 in prostate, breast, and cervical cancer cells[J]. Int J Oncol, 2000, 17(1): 23 -28.
  • 7Yang S F, Yuan S S, Yeh Y T, et al. The role of pSTAT3 (ser727) revealed by its association with Ki-67 in cervical intra epithelial neoplasia[J]. Gynecol Oncol 2005, 98(3):446-452.
  • 8Yang S F, Yuan S S,Yeh Y T, et al. Positive association between STAT3 and Ki-67 in cervical intraepithelial neoplasia[J]. Kaohsiung J Med Sci,2006, 22(11) :539-546.
  • 9Marian B, Sizhi P G, Simi A, etal. Star3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer[J]. Breast Cancer Res, 2007, 9(3) :32.
  • 10童丹,宋文静.IL-17、IL-6和TGF-β_1在宫颈上皮内瘤变和宫颈癌中的表达及临床意义[J].中国妇幼保健,2014,29(24):3984-3986. 被引量:16

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部